Improving competitiveness amid ongoing pressure on prices and healthcare system reimbursements 

Medical device manufacturers are now facing the arrival of new, more agile entrants with a strong capacity for innovation and a naturally service-oriented approach. To remain competitive, established players must identify new sources of external or internal growth. Key Solutions Include: Design-to-Cost  and Digital, to cut costs and invent new services with high added value. In fact, the future of medicine, based on Big Data, lies in an individualized approach that takes the unique characteristics of each patient into account. Adopting this precision and personalized medicine comes with major challenges, i.e. how to make the current machines and facilities suitable for manufacturing smaller batches. 

Pharmaceutical manufacturers, on the other hand, need to keep up with the latest developments in research and innovation, constantly adapting their organization and processes to capture the best opportunities. Between the rapid growth of generic medications, new technologies, the changing regulatory framework and the deficit in healthcare reimbursement systems, these players need to control their investments and adjust their OPEX in order to improve the profitability of their plants, future plants, etc.). Avencore has experience with winning strategies in sectors that are undergoing transformation: optimizing investments, changing operational models, integrating and aligning strategic partners.

Our dependence on Asia for the supply of active ingredients leaves pharmaceutical companies exposed to the risk of supply shortages and rising costs. At the same time, the unpredictable nature of demand and the varying lifespans of products make inventory management particularly complex. To strengthen their supply chain resilience, Avencore helps its customers diversify suppliers and invest in innovative technologies in order to bring part of the production of active ingredients back to Europe.